EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging

Emilie Pauline Buddingh iD, Mary Slatter, Juan Carlos Aldave Becerra, Laura Alonso Garcia, Erik von Asmuth, Safa Baris, Oscar de la Calle-Martín, Alice Y Chan, Su-Wan Bianca Chan, Shanmuganathan Chandrakasan, Deepakbabu Chellapandian, Jasmeen Dara und 29 weitere

Journal of Human Immunity · 01.09.2025 · 1 (3)

DOI: 10.70962/jhi.20250027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 30.07.2025. Verfasst von Emilie Pauline Buddingh und 40 weiteren Autor:innen. Beteiligte Einrichtung: Willem-Alexander Children's Hospital, Department of Pediatrics, Pediatric Stem cell Transplantation program, Leiden University Medical Center, Leiden…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are associated with infections, including chronic mucocutaneous candidiasis and autoimmunity. Morbidity is high, and disease manifestations can be life-threatening. Curative allogeneic hematopoietic stem cell transplantation (HSCT) historically has had poor outcomes. We identified 36 patients with STAT1 GOF disease, receiving 40 HSCT procedures in 2010–2023, in a combined effort of the EBMT-IEWP and the PIDTC. Median age at first transplant was 11 years (range 1–33). Indications for HSCT were combined immunodeficiency, severe and/or refractory infections, and autoimmunity. Acute GvHD occurred in 22/40 HSCT procedures; 5 patients suffered from grade III/IV acute GvHD. One patient had chronic GvHD. Overall survival was 72.2%, and event-free survival was 55.6%, markedly improved from an earlier report on HSCT for STAT1 GOF disease. Patients with an HCT-CI score of 1 or higher had worse outcome. Pre-treatment with Janus kinase (JAK) inhibitors was associated with better event-free survival.

Autor:innen und Institutionen

  • Willem-Alexander Children's Hospital, Department of Pediatrics, Pediatric Stem cell Transplantation program, Leiden University Medical Center, Leiden, The Netherlands.
  • Haematopoietic Stem Cell Transplantation department, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle, United Kingdom.
  • Allergy and Immunology, Hospital Rebagliati, Lima, Peru.
  • Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain.
  • Division of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
  • Universitat Autònoma de Barcelona, Spain.

ORCID-Profile: Emilie Pauline Buddingh, Catharina Schuetz

Förderung

  • NCATS NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
  • Office of Rare Diseases Research
  • National Center for Advancing Translational Sciences
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Buddingh, E. P., Slatter, M., Becerra, J. C. A., Garcia, L. A., von Asmuth, E., Baris, S., de la Calle-Martín, O., Chan, A. Y., Chan, S. B., Chandrakasan, S., Chellapandian, D., Dara, J., Farmand, S., Fasth, A., Satter, L. F., Formankova, R., Grunebaum, E., Keogh, S. J., Kiykim, A., …, & Schuetz, C. (2025). Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging. Journal of Human Immunity, 1(3). https://doi.org/10.70962/jhi.20250027

Vancouver

Buddingh EP, Slatter M, Becerra JCA, Garcia LA, von Asmuth E, Baris S, et al. Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging. Journal of Human Immunity. 2025;1(3). doi:10.70962/jhi.20250027

BibTeX
@article{Buddingh2025,
  author = {Buddingh, Emilie Pauline and Slatter, Mary and Becerra, Juan Carlos Aldave and Garcia, Laura Alonso and von Asmuth, Erik and Baris, Safa and de la Calle-Martín, Oscar and Chan, Alice Y and Chan, Su-Wan Bianca and Chandrakasan, Shanmuganathan and Chellapandian, Deepakbabu and Dara, Jasmeen and Farmand, Susan and Fasth, Anders and Satter, Lisa Forbes and Formankova, Renata and Grunebaum, Eyal and Keogh, Steven J and Kiykim, Ayça and Kühl, Jörn-Sven and Laberko, Alexandra and Leahy, Timothy Ronan and Lindemans, Caroline and Martinez, Caridad and Martínez-Martínez, Laura and Mitchell, William Glenn and Morris, Emma and Oved, Joseph H and Polacik, Maria and Rivière, Jacques G and Roifman, Chaim M and Kilic, Sara Sebnem and Sedlacek, Petr and Shah, Ami J and Vong, Linda and Lankester, Arjan C and Albert, Michael H and Neven, Bénédicte and Torgerson, Troy and Leiding, Jennifer and Schuetz, Catharina},
  title = {Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging},
  journal = {Journal of Human Immunity},
  year = {2025},
  volume = {1},
  number = {3},
  doi = {10.70962/jhi.20250027}
}
Kostenlos starten →